Skip to content
Screener

ANI Pharmaceuticals ANIP Net Change in Cash

Net Change in Cash at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$64.79M-524%
Viatris logo
ViatrisVTRS
-$915.7M-386%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$10.27M+142%
ALN
Alnylam PharmaceuticalsALNY
$53.61M0.0%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$6.28M-353%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$138.82M+1,134%

Other financials

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.88B+25.6%
Enterprise value$1.82B+14.3%
P/E17.3×
P/S1.9×-0.1×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001023024-26-000069
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Payment of Novitium Contingent Consideration(80)
Net Cash and Cash Equivalents Used in Financing Activities(26,263)(11,653)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash223544
Net Change in Cash, Cash Equivalents, and Restricted Cash74,62672,939
Cash, cash equivalents, and restricted cash, beginning of period285,621144,894
Cash, cash equivalents, and restricted cash end of period$360,247$217,833
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents$285,585$144,894

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's net change in cash?
ANI Pharmaceuticals (ANIP) reported net change in cash of $49.04M in Q2 2026.
How has ANI Pharmaceuticals's net change in cash changed year-over-year?
ANI Pharmaceuticals's net change in cash decreased by 27.9% year-over-year, from $68M to $49.04M.
What is the long-term trend for ANI Pharmaceuticals's net change in cash?
Over 3 years (2022 to 2025), ANI Pharmaceuticals's net change in cash has grown at a 39.3% compound annual growth rate (CAGR), from -$52.07M to $140.73M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about ANI Pharmaceuticals's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude